{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-25-000062","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.220845+00:00","generated_at":"2026-05-18T01:55:22.822294+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"West Pharma beats Q2, raises FY 2025 guidance; declares Q4 dividend","bullets":["Net sales $766.5M (+9.2% YoY); diluted EPS $1.82 vs $1.51; adjusted EPS $1.84 vs $1.52.","FY 2025 net sales guidance raised to $3.04-3.06B (from $2.945-2.975B); adjusted EPS raised to $6.65-6.85.","Proprietary Products sales $619.8M (+10.7%); HVP components up 11.3% driven by GLP-1 elastomer growth.","Board declares Q4 dividend $0.22/share, payable Nov 19, record Nov 12.","First-half 2025 free cash flow $160M (from $92.4M); repurchased 552,593 shares for $134M."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-25-000062","json":"https://secwatch.observer/filing/0000105770-25-000062.json","markdown":"https://secwatch.observer/filing/0000105770-25-000062.md","text":"https://secwatch.observer/filing/0000105770-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000062/0000105770-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000062/wst-20250724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:55:22.822294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}